Phase 3 Trials Show GSK’s Nucala Can Reduce Exacerbations in Specific COPD Patients
Two Phase 3 clinical trials demonstrated that the antibody Nucala (mepolizumab) from GlaxoSmithKline has a moderate efficacy in the reduction of the rate of exacerbations in chronic obstructive pulmonary disease (COPD) patients. The almost 20 percent decrease in the exacerbation rate was only observed in COPD patients with high levels of…